# To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

> **NCT06833983** · PHASE3 · RECRUITING · sponsor: **Gritgen Therapeutics Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** GS1191-0445 injection

## Key facts

- **NCT ID:** NCT06833983
- **Lead sponsor:** Gritgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2026-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06833983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06833983, "To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06833983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*